Stocks Listing
EQRX

EQRx, Inc.

Share
EQRX
$5.03 2.03%Last Updated Sep 30 2022 07:56 PM
1D Low / 1D High
Low:$4.86
High:$5.22
1D
2.03%
5D
11.28 %
30D
2.44 %
BulletPurple
Market Cap
$2,251,908,608
1.52 %
2.3 B
BulletBlue
Volume 1D
1,321,785
-
1.3 M
BulletOrange
Circulating Supply
448,141,017 EQRX
448.1 M

Price Chart

1D
5D
1M
6M
YTD
1Y
MAX
About

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase I clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Historical data

1D
5D
1M
6M
1Y
MAX
Day
Open - Close
Low/High
Volume
Market Cap
Show More
Market Status
Closed
NGM
NASDAQ Stock Exchange
USA
Opens in
1 minutes
Working Hours
Mon-Fri, 01:30 PM - 08:00 PM
Timezone
GMT+0